The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal ...

Iclusig, a kinase inhibitor, received a positive opinion for use alongside low-intensity chemotherapy in adults with newly identified disease.

Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80mg, 100 mg, and 140 mg are bioequivalent to Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company, and indicated fo ...

The authors’ approach is deceptively simple: take an aldehyde dehydrogenase enzyme, which naturally converts aldehydes to acids, and get it to react with an amine instead of water. But actually making ...

February 4, 2026Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GISTNovel Mechanism of ...

Dasatinib Tablets (RLD Sprycel®) had an estimated annual sale of USD 930 million in the U.S. (IQVIA MAT Oct 2025).

The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...

Our Bureau, Mumbai Monday, February 2, 2026, 15:40 Hrs [IST] Global pharma major Lupin Limited (Lupin) announced the launc ...

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the 11 Best Performing Stocks in the Last 12 Months. On January 26, 2026, ...

Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 ...

The FDA previously agreed to accept Cogent’s New Drug Application (NDA) under the Real-Time Oncology Review program, which ...

PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus ...